hydroxyurea has been researched along with Glioma in 28 studies
Glioma: Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 9.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 9.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 8.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| "The parallel effects of simvastatin on cell cycle and PKC activity in rat C6 glioma cells were investigated." | 7.69 | PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment. ( Baetta, R; Battaini, F; Bergamaschi, S; Davegna, C; De Renzis, MR; Fumagalli, R; Govoni, S; Soma, MR, 1994) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 7.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 7.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 7.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 7.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "This study determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, vatalanib, when administered with imatinib and hydroxyurea on a continuous daily schedule among recurrent malignant glioma patients." | 5.14 | Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. ( Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ, 2009) |
| "Within 3 weeks of definitive surgery, 571 adult patients with histologically confirmed, supratentorial malignant gliomas were randomly assigned to receive one of three chemotherapy regimens: BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) alone, alternating courses (every 8 weeks) of BCNU and procarbazine, or BCNU plus hydroxyurea alternating with procarbazine plus VM-26 (epipodophyllotoxin)." | 5.06 | Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. ( Burger, PC; Green, SB; Mahaley, MS; Mealey, J; Ransohoff, J; Robertson, JT; Selker, RG; Shapiro, WR; Strike, TA; VanGilder, JC, 1989) |
| "The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas." | 5.05 | Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. ( Davis, RL; Gutin, PH; Levin, VA; Nutik, S; Resser, KJ; Vestnys, P; Wara, WM; Wilson, CB; Yatsko, K, 1985) |
| "To assess the effectiveness and safety of procarbazine, lomustine, and vincristine (PCV) chemotherapy with other interventions in adults with recurrent high-grade glioma." | 4.95 | Procarbazine, lomustine and vincristine for recurrent high-grade glioma. ( Guo, J; Parasramka, S; Rosenfeld, M; Talari, G; Villano, JL, 2017) |
| " We show here that antisense suppression of WRN in two human glioma cell lines reproduces hallmarks of the drug cytotoxicity profile of WS cells, namely, hypersensitivity to 4-nitroquinoline 1-oxide, camptothecin and hydroxyurea." | 3.72 | The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function. ( Blank, A; Bobola, MS; D Kolstoe, D; Gold, B; Loeb, LA; Meade, EH; Rabinovitch, PS; Silber, JR; Varadarajan, S, 2004) |
| "The parallel effects of simvastatin on cell cycle and PKC activity in rat C6 glioma cells were investigated." | 3.69 | PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment. ( Baetta, R; Battaini, F; Bergamaschi, S; Davegna, C; De Renzis, MR; Fumagalli, R; Govoni, S; Soma, MR, 1994) |
| "Our results indicate that chemotherapy with a combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea is active for patients with recurrent anaplastic gliomas and glioblastomas not previously treated with nitrosourea-based chemotherapy but is inactive for patients with glioblastomas previously treated with chemotherapy." | 3.69 | Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas. ( Bruner, J; Flowers, A; Gleason, MJ; Ictech, SE; Jaeckle, KA; Kyritsis, AP; Levin, VA; Yung, WK, 1996) |
| " Before the appearance of CMML, he received a total dose of 2,894 mg of nimustine for the treatment of a pontine glioma over 12 years." | 3.69 | Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14). ( Amemiya, Y; Hatake, K; Miura, Y; Miyata, T; Muroi, K; Saito, M, 1996) |
| "Twenty-eight evaluable children with the diagnosis of brain stem glioma were treated with 5-fluorouracil and CCNU before posterior fossa irradiation (5500 rads); during irradiation, the children received hydroxyurea and misonidazole." | 3.67 | 5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group. ( Allen, J; Edwards, MS; Levin, VA; Ortega, J; Vestnys, P; Wara, WM, 1984) |
| "The Neuro-oncology Service of the University of California Brain Tumor Research Center conducted a nonrandomized phase II study to evaluate, in patients with recurrent malignant glioma, the benefit of a four-drug combination (BFHM) consisting of carmustine (1,3-bis (2-chloroethyl)-1-nitrosourea), 5-fluorouracil, hydroxyurea, and 6-mercaptopurine." | 3.67 | Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas. ( Berger, M; Chamberlain, M; Choucair, A; Da Silva, V; Davis, RL; Levin, VA; Liu, HC; Murovic, J; Phuphanich, S; Seager, M, 1986) |
| "Twenty-one patients with recurrent malignant central nervous system gliomas were treated with a combination of 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine." | 3.67 | Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine. ( Edwards, MS; Fulton, D; Levin, V; Prados, M; Rodriguez, LA; Silver, P, 1988) |
| "The rats implanted with 9L gliosarcoma were dosed orally with hydroxyurea and L-arginine." | 1.35 | Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors. ( Black, KL; Espinoza, AJ; Hu, J; Irvin, DK; Ko, MK; Konda, BM; Ong, JM; Sacapano, MR; Shu, Y; Wang, X; Yin, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (60.71) | 18.7374 |
| 1990's | 7 (25.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 1 (3.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Parasramka, S | 1 |
| Talari, G | 1 |
| Rosenfeld, M | 1 |
| Guo, J | 1 |
| Villano, JL | 1 |
| Yin, D | 1 |
| Wang, X | 1 |
| Konda, BM | 1 |
| Ong, JM | 1 |
| Hu, J | 1 |
| Sacapano, MR | 1 |
| Ko, MK | 1 |
| Espinoza, AJ | 1 |
| Irvin, DK | 1 |
| Shu, Y | 1 |
| Black, KL | 1 |
| Reardon, DA | 1 |
| Egorin, MJ | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Beumer, JH | 1 |
| Lagattuta, TF | 1 |
| Gururangan, S | 1 |
| Herndon, JE | 1 |
| Salvado, AJ | 1 |
| Friedman, HS | 1 |
| Blank, A | 1 |
| Bobola, MS | 1 |
| Gold, B | 1 |
| Varadarajan, S | 1 |
| D Kolstoe, D | 1 |
| Meade, EH | 1 |
| Rabinovitch, PS | 1 |
| Loeb, LA | 1 |
| Silber, JR | 1 |
| Levin, VA | 9 |
| Edwards, MS | 2 |
| Wara, WM | 5 |
| Allen, J | 1 |
| Ortega, J | 1 |
| Vestnys, P | 2 |
| Brock, WA | 1 |
| Trostle-Weige, PK | 1 |
| Williams, M | 1 |
| Meistrich, ML | 1 |
| Wilson, CB | 5 |
| Vestnys, PS | 1 |
| Chicoine, MR | 1 |
| Silbergeld, DL | 1 |
| Soma, MR | 1 |
| Baetta, R | 1 |
| Bergamaschi, S | 1 |
| De Renzis, MR | 1 |
| Davegna, C | 1 |
| Battaini, F | 1 |
| Fumagalli, R | 1 |
| Govoni, S | 1 |
| Kyritsis, AP | 1 |
| Yung, WK | 1 |
| Jaeckle, KA | 1 |
| Bruner, J | 1 |
| Gleason, MJ | 1 |
| Ictech, SE | 1 |
| Flowers, A | 1 |
| Muroi, K | 1 |
| Miyata, T | 1 |
| Saito, M | 1 |
| Hatake, K | 1 |
| Amemiya, Y | 1 |
| Miura, Y | 1 |
| Prados, MD | 3 |
| Larson, DA | 2 |
| Lamborn, K | 1 |
| McDermott, MW | 1 |
| Sneed, PK | 2 |
| Chang, SM | 1 |
| Mack, EE | 1 |
| Krouwer, HG | 1 |
| Chandler, KL | 1 |
| Warnick, RE | 1 |
| Davis, RL | 3 |
| Rabbitt, JE | 1 |
| Malec, M | 1 |
| Gutin, PH | 3 |
| Phillips, TL | 2 |
| Davis, R | 2 |
| Pischer, TL | 2 |
| Irwin, L | 2 |
| Wara, W | 1 |
| Zänker, KS | 1 |
| Stavrou, D | 1 |
| Osterkamp, U | 1 |
| Wriedt-Lübbe, I | 1 |
| Blümel, G | 1 |
| Wayss, K | 1 |
| Mattern, J | 1 |
| Schuhmacher, J | 1 |
| Volm, M | 1 |
| Weaver, KA | 1 |
| Shapiro, WR | 2 |
| Green, SB | 1 |
| Burger, PC | 1 |
| Mahaley, MS | 2 |
| Selker, RG | 1 |
| VanGilder, JC | 1 |
| Robertson, JT | 1 |
| Ransohoff, J | 1 |
| Mealey, J | 1 |
| Strike, TA | 1 |
| Resser, KJ | 1 |
| Yatsko, K | 1 |
| Nutik, S | 1 |
| Phuphanich, S | 1 |
| Liu, HC | 1 |
| Da Silva, V | 1 |
| Murovic, J | 1 |
| Choucair, A | 1 |
| Chamberlain, M | 1 |
| Berger, M | 1 |
| Seager, M | 1 |
| Shapiro, JR | 1 |
| Rodriguez, LA | 1 |
| Prados, M | 1 |
| Fulton, D | 1 |
| Silver, P | 1 |
| Levin, V | 1 |
| Chastagner, P | 1 |
| Olive, D | 1 |
| Philip, T | 1 |
| Zucker, JM | 1 |
| Czorny, A | 1 |
| Lapras, C | 1 |
| Brunat-Mentigny, M | 1 |
| Whaley, RA | 1 |
| Krigman, MR | 1 |
| Bouldin, TW | 1 |
| Bertsch, L | 1 |
| Cush, S | 1 |
| Biegel, JA | 1 |
| Leslie, DS | 1 |
| Bigner, DD | 1 |
| Bigner, SH | 1 |
| Broder, LE | 1 |
| Rall, DP | 1 |
| Sugiura, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea[NCT00387933] | Phase 1 | 37 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for hydroxyurea and Glioma
| Article | Year |
|---|---|
Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytarabine; Dacarbazine; Dis | 2017 |
Principles of brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; | 1986 |
Chemotherapy of brain tumors.
Topics: Adult; Antineoplastic Agents; Azaguanine; Bleomycin; Brain Neoplasms; Child; Cyclophosphamide; Drug | 1972 |
7 trials available for hydroxyurea and Glioma
| Article | Year |
|---|---|
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Gl | 2009 |
Primary intracranial gliomas: clinical studies and treatment regimens of the Brain Tumor Research Center, University of California, San Francisco, 1977-1979.
Topics: Antineoplastic Agents; Brain Neoplasms; California; Carmustine; Clinical Trials as Topic; Drug Thera | 1981 |
A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Cobalt Radioisotope | 1979 |
Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation.
Topics: Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Therapy, Combination; Glioblastoma; Glio | 1979 |
Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cerebellar Neoplasms; Clinical Trials as | 1989 |
Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Trials as Topic; C | 1985 |
Randomized phase III trial of single versus multiple chemotherapeutic treatment following surgery and during radiotherapy for patients with anaplastic gliomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Clinical Trials as Topi | 1987 |
18 other studies available for hydroxyurea and Glioma
| Article | Year |
|---|---|
Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors.
Topics: Administration, Oral; Animals; Arginine; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeabilit | 2008 |
The Werner syndrome protein confers resistance to the DNA lesions N3-methyladenine and O6-methylguanine: implications for WRN function.
Topics: 4-Nitroquinoline-1-oxide; Adenine; Alkylating Agents; Antineoplastic Agents; Apoptosis; Camptothecin | 2004 |
5-Fluorouracil and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) followed by hydroxyurea, misonidazole, and irradiation for brain stem gliomas: a pilot study of the Brain Tumor Research Center and the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Bra | 1984 |
Histone and DNA synthesis in differentiating and rapidly proliferating cells in vivo and in vitro.
Topics: Animals; Animals, Newborn; Brain Neoplasms; Cell Cycle; Cell Differentiation; Cell Line; DNA Replica | 1983 |
Assessment of brain tumor cell motility in vivo and in vitro.
Topics: Amidines; Animals; Astrocytoma; Brain Neoplasms; Cell Movement; Clone Cells; Cytochalasin B; Fibrone | 1995 |
PKC activity in rat C6 glioma cells: changes associated with cell cycle and simvastatin treatment.
Topics: Animals; Astrocytoma; Cell Cycle; Demecolcine; Glioma; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 1994 |
Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Pr | 1996 |
Therapy-related chronic myelomonocytic leukaemia with bone marrow eosinophilia associated with der(11)t(1;11)(q21;q14).
Topics: Antineoplastic Agents; Bone Marrow; Brain Neoplasms; Child; Chromosome Aberrations; Eosinophilia; Fa | 1996 |
Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1998 |
Fibrinolysis induced by rat glioma cells. A mitosis-triggered process?
Topics: Animals; Astrocytoma; Cell Line; Dactinomycin; Fibrin Fibrinogen Degradation Products; Fibrinolysis; | 1978 |
[Incorporation of a 131-iodine-deoxycytidine monophosphate protamine complex into the DNA of tumor-bearing rats following partial synchronization with hydroxyurea].
Topics: Animals; Deoxycytidine; DNA, Neoplasm; Glioma; Hydroxyurea; Iodine Radioisotopes; Isotope Labeling; | 1975 |
Treatment of recurrent gliomas and metastatic brain tumors with a polydrug protocol designed to combat nitrosourea resistance.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle | 1992 |
Brachytherapy of brain tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Brain Neoplasms; Child; Combined Moda | 1992 |
Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1986 |
Treatment of recurrent brain stem gliomas and other central nervous system tumors with 5-fluorouracil, CCNU, hydroxyurea, and 6-mercaptopurine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Chil | 1988 |
[Efficacy of the "8 drugs in a day" protocol in brain tumors in children].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cer | 1988 |
Hydroxyurea synchronization increases mitotic yield in human glioma cell lines.
Topics: Cell Cycle; Cell Line; DNA, Neoplasm; Flow Cytometry; Glioma; Humans; Hydroxyurea; Karyotyping; Mito | 1987 |
Effect of 1,3-bis(2-chloroethyl)-1-nitrosourea (NSC-409962) and two related compounds on a spectrum of tumors.
Topics: Adenocarcinoma; Animals; Carcinoma, Ehrlich Tumor; Carcinoma, Krebs 2; Fibrosarcoma; Glioma; Hydroxy | 1967 |